Skip to main content

Table 2 Univariate analysis

From: Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab

Factor

Responder

Non-responder

p value

(N = 108)

(N = 52)

Age > 70 years

59 (54.6)

29 (55.8)

0.8920

Female sex

16 (14.8)

10 (19.2)

0.4782

ECOG PS score ≥ 2

15 (13.9)

13 (25.0)

0.0832

Stage: IV, recurrence

81 (75.0)

46 (88.5)

0.0487

Squamous cell carcinoma

29 (26.9)

15 (28.9)

0.7913

Never smoker

9 (8.3)

5 (9.6)

0.7881

PD-L1 50–89%

65 (60.2)

39 (75.0)

0.0657

Steroid use

3 (2.8)

6 (11.5)

0.0243

Metastasis Brain

14 (13.0)

12 (23.1)

0.1043

 Liver

12 (11.1)

8 (15.4)

0.4439

 Bone

28 (25.9)

14 (26.9)

0.8932

 Adrenal

17 (15.7)

10 (19.2)

0.5809

 Pulmonary

31 (28.7)

20 (38.5)

0.2148

 Pleural effusion

17 (15.7)

19 (36.5)

0.0032

Laboratory data

 Neutrophil-to-lymphocyte ratio (< 3)

30 (27.8)

14 (26.9)

0.9097

 C-reactive protein (< 1.0 mg/dL)

54 (50.0)

17 (32.7)

0.0390

 Lactate dehydrogenase (< 240 IU/L)

79 (73.2)

33 (63.5)

0.2105

 Albumin (< 3.5 g/dL)

47 (43.5)

26 (50.0)

0.4407

  1. ECOG PS Eastern Cooperative Oncology Group performance status, PD-L1 programmed cell death ligand 1